Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

34.64 -0.07 (-0.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39,481,654
Open 34.83
Bid (Size) 33.70 (100)
Ask (Size) 36.26 (300)
Prev. Close 34.71
Today's Range 34.02 - 35.34
52wk Range 11.94 - 37.97
Shares Outstanding 692,072,184
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately ↗
Roivant Sciences (NASDAQ:ROIV) said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered... 
Via MarketBeat
Topics Government
News headline image
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
From Roivant Sciences
Via GlobeNewswire

Performance

YTD
+58.0%
+58.0%
1 Month
+2.2%
+2.2%
3 Month
+19.1%
+19.1%
6 Month
+23.3%
+23.3%
1 Year
+179.6%
+179.6%

More News

Read More
News headline image
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
From Roivant Sciences
Via GlobeNewswire
News headline image
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
From Roivant Sciences
Via GlobeNewswire
ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings ↗
Via Chartmill
News headline image
Roivant Sciences Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings Government
News headline image
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? ↗
Via The Motley Fool
News headline image
Roivant (ROIV) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Roivant Sciences Q4 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings Government
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
Via The Motley Fool
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗
Via The Motley Fool
News headline image
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
Via MarketMinute
Topics Intellectual Property
News headline image
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
From Roivant Sciences
Via GlobeNewswire
News headline image
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
From Roivant Sciences
Via GlobeNewswire
News headline image
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
From Roivant Sciences
Via GlobeNewswire
News headline image
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
Via The Motley Fool
News headline image
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
Via MarketMinute
Topics Intellectual Property Lawsuit

Frequently Asked Questions

Is Roivant Sciences Ltd. - Common Shares publicly traded?
Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.
What exchange does Roivant Sciences Ltd. - Common Shares trade on?
Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?
The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market
What is the current price of Roivant Sciences Ltd. - Common Shares?
The current price of Roivant Sciences Ltd. - Common Shares is 34.64
When was Roivant Sciences Ltd. - Common Shares last traded?
The last trade of Roivant Sciences Ltd. - Common Shares was at 08/31/26 04:00 PM ET
What is the market capitalization of Roivant Sciences Ltd. - Common Shares?
The market capitalization of Roivant Sciences Ltd. - Common Shares is 23.97B
How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?
Roivant Sciences Ltd. - Common Shares has 24B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.